17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management

17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management

Epidemiology, Risk Factors and Genetic Syndromes

Basal cell carcinoma (BCC) is the most common cancer diagnosed in humans worldwide, accounting for approximately 80% of all non-melanoma skin malignancies. In European populations, the incidence continues to rise steadily, exceeding 100 to 150 cases per 100,000 person-years in Northern Europe and reaching higher levels in southern regions and populations with light skin phenotypes (Fitzpatrick types I and II).

Etiologic Factors

• Ultraviolet Radiation Dynamics: Unlike cutaneous squamous cell carcinoma (which correlates with cumulative lifetime UV dose), BCC is strongly associated with intense, intermittent solar ultraviolet exposure (particularly severe, blistering sunburns sustained during childhood and adolescence) as well as artificial UV tanning bed use.
• Additional Risk Factors: Ionizing radiation (occupational or historic therapeutic radiation for acne or tinea capitis), chronic arsenic ingestion, Fitzpatrick skin types I and II, red or blonde hair, light eye color, and iatrogenic immunosuppression following solid organ transplantation or for hematologic malignancies.

Gorlin-Goltz Syndrome (Naevoid Basal Cell Carcinoma Syndrome)

Gorlin-Goltz syndrome (NBCCS) is a rare, autosomal dominant genodermatosis with near-complete penetrance and variable expressivity, mapped to chromosome 9q22.3:

• Genetic Etiology: Germline heterozygous loss-of-function mutations in the PTCH1 (Patched-1) gene. Second-hit somatic inactivation of the remaining normal PTCH1 allele in basal keratinocytes triggers explosive, constitutive activation of the Hedgehog signaling pathway.
• Diagnostic Criteria (Kimonis 1997): Diagnosis requires either two major criteria, or one major plus two minor criteria:

[!CAUTION] Avoid Radiotherapy in Gorlin-Goltz Syndrome: Ionising radiotherapy should be avoided whenever possible in Gorlin-Goltz syndrome. Radiotherapy induces rapid, catastrophic emergence of hundreds of secondary, invasive BCCs across the irradiated field due to massive DNA damage in cells already missing one functional PTCH1 allele.

Other Rare Syndromic Associations

• Bazex-Dupré-Christol Syndrome: X-linked dominant disorder featuring follicular atrophoderma ("ice-pick" marks on dorsal hands/elbows), multiple early facial BCCs, hypotrichosis, and localized hypohidrosis.
• Rombo Syndrome: Autosomal dominant condition characterized by vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, and multiple BCCs emerging in the fourth decade.

---

Molecular Pathogenesis: The Hedgehog Signaling Cascade

Constitutive, ligand-independent hyperactivation of the Hedgehog (Hh) signaling pathway is the universal, pathognomonic driver event present in >95% of all sporadic and hereditary basal cell carcinomas.

PHYSIOLOGICAL STATE (Pathways OFF):         ONCOGENIC ACTIVATION IN BCC (Pathway ON):

     No Hh Ligand                              No Hh Ligand Needed
          │                                             │
          ▼                                             ▼
      ┌───────┐                                     ┌───────┐
      │ PTCH1 │ (Active Repressor)                  │ PTCH1 │ (Inactivated by mutation / LOH)
      └───┬───┘                                     └───┬───┘
          │ Tonically Inhibits                          │ Loss of Repression!
          ▼                                             ▼
      ┌───────┐                                     ┌───────┐
      │  SMO  │ (Held Inactive)                     │  SMO  │ (Constitutively Active / Phosphorylated)
      └───┬───┘                                     └───┬───┘
          │                                             │ Translocates to Primary Cilium
          ▼                                             ▼
   GLI Factors Sequestered /                     GLI Transcription Factors (GLI1 / GLI2)
   Target Genes Suppressed                       Translocate into Nucleus
                                                        │
                                                        ▼
                                                 Target Gene Transcription:
                                                 • BCL-2 (Inhibits Apoptosis)
                                                 • Cyclin D1 (Drives Cell Cycle)
                                                 • VEGF (Stimulates Angiogenesis)
                                                 • GLI1 & PTCH1 (Positive/Negative Feedback)

Normal Physiology of Hedgehog Signaling

In quiescent physiological states, the 12-pass transmembrane receptor Patched-1 (PTCH1) acts as a catalytic repressor, tonically preventing the 7-transmembrane G-protein-coupled-like receptor Smoothened (SMO) from translocating to the primary cilium. When an extracellular Hedgehog ligand (Sonic Hedgehog [SHH], Indian Hedgehog [IHH], or Desert Hedgehog [DHH]) binds to PTCH1, the tonic inhibition of SMO is relieved. Free SMO phosphorylates and moves to the primary cilium, triggering dissociation of the GLI zinc-finger transcription factors (GLI1, GLI2, and GLI3) from the inhibitory SuFu (Suppressor of Fused) complex. Activated GLI1 and GLI2 translocate into the nucleus, binding target promoters to activate genes governing proliferation, survival, and tissue patterning.

Oncogenic Alterations in BCC

1. PTCH1 Loss of Function (~70–90% of Sporadic BCCs): Inactivating mutations in PTCH1 (predominantly UV-signature C→T and CC→TT transitions) combined with loss of heterozygosity (LOH) on 9q22 permanently eliminate the repressor protein. Uninhibited SMO signaling becomes constitutively active in the absence of any Hedgehog ligand.
2. SMO Activating Mutations (~10–20% of Sporadic BCCs): Activating point mutations in SMO (e.g., SMO W535L or SMO L412F) render the Smoothened receptor insusceptible to PTCH1 repression, causing continuous downstream signaling.
3. Secondary Mutations: Over 60% of BCCs harbor concomitant UV-signature mutations in the TP53 tumor suppressor gene, as well as alterations in MYCN, PTPN14, and epigenetic histone modifiers.

---

Clinical and Histopathologic Subtypes

Basal cell carcinomas exhibit distinct clinical morphologies and histological architectures that directly dictate biological behavior, invasion patterns, and recurrence risks.

1. Nodular Basal Cell Carcinoma (~60% of Cases)

• Clinical Presentation: The archetypal and most prevalent variant. Presents as a firm, pearly, translucent, dome-shaped papule or nodule with rolled, elevated borders and prominent, delicate, branching arborising telangiectasias coursing across its surface. As the tumor enlarges, the center frequently undergoes ischemic necrosis and ulceration, creating a crusted central crater historically known as a "rodent ulcer". Most common on the sun-exposed face (cheeks, forehead, nose, nasolabial folds).
• Histopathology: Large, well-circumscribed, round-to-oval lobules and cohesive islands of basaloid cells extending from the epidermis into the reticular dermis. Key diagnostic features:
  • Peripheral Palisading: The outermost single row of columnar basaloid cells lines up in a neat, parallel, picket-fence arrangement perpendicular to the tumor margin.
  • Peritumoural Retraction Clefting: During tissue processing and formalin fixation, the delicate mucin-rich stroma shrinks away from the cohesive basaloid nests, leaving clear, empty retraction spaces. This artifactual clefting is a reliable histological hallmark distinguishing BCC from other cutaneous adnexal neoplasms (such as trichoepithelioma).
  • Mucinous Dermal Stroma: Abundant blue-gray ground substance (hyaluronic acid and sulfated glycosaminoglycans) surrounding the tumor nests.

2. Superficial Basal Cell Carcinoma (~15–20% of Cases)

• Clinical Presentation: Slowly expanding, well-demarcated, erythematous, pink macule, patch, or thin plaque with minimal induration. Surface exhibits delicate dry scaling, fine crusting, and a pathognomonic, thread-like, slightly raised pearly border that is best visualized by stretching the skin under sidelighting or dermoscopy. Predominantly located on the trunk, shoulders, and back in younger adults. Frequently misdiagnosed as nummular eczema, plaque psoriasis, or Bowen disease.
• Histopathology: Multiple small, discrete buds, cords, and islands of basaloid cells originating directly from the undersurface of the basal layer of the epidermis, confined entirely to the superficial papillary dermis. Characterized by peripheral palisading and narrow retraction clefts around individual dermal buds, separated by normal intervening epidermis.

3. Morphoeic (Infiltrative / Sclerosing) Basal Cell Carcinoma (~5–10% of Cases)

• Clinical Presentation: Deceptively innocuous, scar-like, indurated, firm, flat or slightly depressed, ivory-white, yellowish, or porcelain-colored plaque. The borders are ill-defined and imperceptible to standard inspection. Lacks typical pearly borders, rolled edges, or surface telangiectasias. Has high biological aggressiveness, relentlessly infiltrating deeply into subcutaneous fat, cartilage, and bone, often extending centimeters beyond visible margins.
• Histopathology: Narrow, elongated, spiky, branching cords and jagged strands of atypical basaloid cells—often only one to two cells thick—deeply embedded in a dense, fibrotic, hyalinized, desmoplastic collagenous stroma. In stark contrast to nodular BCC, peripheral palisading and peritumoural retraction clefting are characteristically absent (the dense collagenous stroma binds tightly to the tumor cords).

4. Pigmented Basal Cell Carcinoma

• Clinical Presentation: Nodular or superficial BCC containing brown, black, or blue-gray pigmentation. May be speckled or solid, often clinically mimicking invasive malignant melanoma, pigmented seborrhoeic keratosis, or blue naevus.
• Histopathology: Features of nodular or superficial BCC with the addition of numerous non-neoplastic, dendritic melanocytes interspersed evenly throughout the basaloid tumor nests. Melanocytes transfer abundant melanin granules into the tumor cells and surrounding dermal melanophages.

5. Basosquamous Carcinoma (Metatypical BCC)

• Clinical Presentation: Aggressive, rapidly enlarging, deeply destructive, indurated, ulcerated plaque or nodule, most often occurring on the central mid-face or ears of elderly patients.
• Histopathology: A hybrid, metatypical malignancy showing areas of classic basaloid BCC transitioning abruptly or gradually into zones of squamous differentiation. The squamatoid cells feature enlarged vesicular nuclei, abundant eosinophilic cytoplasm, intercellular bridges (desmosomes), and individual cell dyskeratosis, lacking peripheral palisading.
• Biological Significance: Unlike standard BCC, basosquamous carcinoma carries substantial metastatic potential (5% to 10% rate of regional lymph node and distant metastasis) and behaves like high-risk cutaneous squamous cell carcinoma, requiring complete surgical clearance and regional staging.

6. Fibroepithelioma of Pinkus (FEP)

• Clinical Presentation: Rare, indolent variant presenting as a solitary, fleshy, soft, pink-to-tan, sessile or pedunculated polypoid nodule, typically on the lower lumbosacral back, buttocks, or groin; mimics an acrochordon or dermal naevus.
• Histopathology: A complex, delicate, anastomosing lattice-work of long, thin cords of basaloid cells embedded within an abundant, pale, fibrovascular stroma.

---

Risk Stratification

The European interdisciplinary guideline (EADO with EDF/EADV partners, updated 2023) classifies BCC as "easy-to-treat" or "difficult-to-treat", with locally advanced and metastatic BCC as separate groups; surgery is first-line for most tumours. For surgical planning, many centres also use the US NCCN low-risk / high-risk model, whose site-and-size cut-offs (H-zone ≥ 6 mm, M-zone ≥ 10 mm, L-zone ≥ 20 mm) appear in the diagram and table below.

                                    BCC Risk Stratification
                                               │
            ┌──────────────────────────────────┴──────────────────────────────────┐
            ▼                                                                     ▼
      LOW-RISK BCC                                                          HIGH-RISK BCC
  • Anatomical Location:                                                • Anatomical Location: Any lesion in
    L-zone (trunk, limbs) or small M-zone                                 HIGH-RISK H-ZONE (central face, eyelids,
  • Size: < 2 cm in L-zone, < 1 cm in M-zone                              nose, lips, ears, temples) OR
  • Histology: Nodular, superficial                                       ≥ 1 cm in M-zone, ≥ 2 cm in L-zone
  • Margins: Well-defined, clinically sharp                             • Histology: Morphoeic, infiltrative,
  • Presentation: Primary (never treated)                                 micronodular, basosquamous, PNI
  • Host: Immunocompetent                                               • Margins: Ill-defined, indistinct
            │                                                           • Recurrence: Any recurrent lesion
            ▼                                                           • Host: Immunosuppressed
   Standard Surgical Excision                                                     │
   with 3-4 mm Clinical Margins                                                   ▼
   (Achieves > 95% histological clearance)                               Mohs Micrographic Surgery (MMS) /
   OR Non-Surgical Options for Superficial                              Complete Circumferential Margin Assessment
   (Imiquimod, 5-FU, Cryosurgery, PDT)                                  (CCDMA) Gold Standard

Definition of Anatomic Risk Zones

• High-Risk "H-Zone" (Face / "Mask" Area): Central face, eyelids, eyebrows, periorbital area, nose, nasolabial folds, lips (cutaneous and vermilion), chin, preauricular and postauricular sulci, ears (helix, antihelix, canal), temples, and genitalia.
• Intermediate-Risk "M-Zone": Forehead, cheeks, scalp, and neck.
• Low-Risk "L-Zone": Trunk, shoulders, and extremities (excluding hands, feet, pretibial, and anogenital skin).

Clinical and Histological Risk Criteria Matrix

---

Surgical and Non-Surgical Management

Standard Surgical Excision and Safety Margins

• Low-Risk Primary BCC: The EADO guideline recommends a 3–4 mm peripheral clinical margin taken down to the subcutaneous fat. In the classic prospective study by Wolf and Zitelli, a 4 mm margin cleared >95% of well-defined primary BCCs under 2 cm.
• High-Risk BCC (when Mohs surgery is unavailable): Standard excision requires wider margins (at least 5 mm, often more), frequently combined with delayed reconstruction until formal histological clearance of all margins is confirmed by permanent paraffin sections.

Mohs Micrographic Surgery (MMS) and CCDMA

Mohs micrographic surgery (MMS)—or its European variant, complete circumferential and deep margin assessment (CCDMA) via frozen or paraffin sectioning—is the established gold standard for high-risk BCCs:

• Technical Principle: The tumor is excised with a narrow initial margin (1–2 mm), beveled at 45 degrees. The specimen is mapped, color-coded with dyes, and sectioned horizontally (en face) so that 100% of the peripheral and deep surgical margins are examined under the microscope. If residual tumor is detected, re-excision is strictly confined to the precise mapped quadrant, preserving uninvolved normal anatomy.
• Indications:
  1. Any BCC in the high-risk facial H-zone.
  2. Aggressive histological subtypes (morphoeic, infiltrative, basosquamous, micronodular).
  3. Recurrent BCCs after prior incomplete treatment.
  4. Tumors with ill-defined clinical borders.
  5. Lesions demonstrating perineural invasion.
  6. Tumors in critical tissue-sparing anatomic locations (eyelids, nose, lips, ears).
• Cure Rates: Mohs surgery achieves a 5-year cure rate of 99% for primary BCCs and ~95% for recurrent BCCs, representing the highest oncology clearance standard.

Non-Surgical Therapies for Low-Risk Superficial BCC

Non-surgical modalities are strictly indicated for primary, low-risk superficial BCCs (and selected small low-risk nodular BCCs in non-critical sites when surgery is contraindicated due to severe patient frailty, anticoagulation, or extensive lesion numbers):

1. Topical Imiquimod 5% Cream: Applied 5 nights per week (Monday through Friday) for 6 weeks. Induces TLR-7-mediated tumor destruction. 5-year clearance rates reach 80% to 85% with excellent cosmetic outcomes.
2. Photodynamic Therapy (MAL-PDT or ALA-PDT): Involves application of MAL or ALA, followed by illumination with red light (630 nm, 37 J/cm²). Standard protocol requires two treatment sessions spaced 1 week apart. Histological clearance ranges from 75% to 85%. Superior cosmetic results make it attractive for large, cosmetically sensitive superficial lesions, but recurrence rates are higher than surgical excision.
3. Cryosurgery: Liquid nitrogen applied using an open-spray technique with a double freeze-thaw cycle of 20 to 30 seconds freeze time per cycle. Carries an increased risk of recurrence and permanent depigmented atrophic scarring.
4. Definitive Radiotherapy: External beam radiotherapy or brachytherapy (total dose 45–60 Gy fractionated over 3–5 weeks) is reserved for elderly, surgically inoperable patients with extensive primary BCC in anatomic areas where surgery would cause unacceptable functional mutilation. Strictly contraindicated in young patients and Gorlin-Goltz syndrome.

---

Advanced, Locally Destructive and Metastatic BCC: Targeted Systemic Therapies

Approximately 1% of BCCs progress to locally advanced or metastatic states:

• Locally Advanced BCC (laBCC): Extensive primary or recurrent disease with deep infiltration into bone, skull base, cartilage, orbit, or dura mater, where curative surgery or radiation is technically impossible or would cause unacceptable cosmetic and functional disfigurement.
• Metastatic BCC (mBCC): Extremely rare (incidence 0.0028% to 0.5% of all BCCs), spreading via lymphatics or blood to regional lymph nodes, lungs, bones, liver, or brain.

Hedgehog Pathway Inhibitors (SMO Antagonists)

Oral, targeted small-molecule inhibitors that directly bind to and block the 7-transmembrane receptor Smoothened (SMO), halting downstream GLI-mediated oncogenic transcription:

1. Vismodegib:
   • Dosing: 150 mg orally once daily, taken continuously until disease progression or unacceptable toxicity.
   • Pivotal Evidence: The ERIVANCE trial demonstrated an objective response rate (ORR) of ~45–60% in locally advanced BCC and ~30–40% in metastatic BCC, with significant tumor downsizing and durable symptom relief.
2. Sonidegib:
   • Dosing: 200 mg orally once daily on an empty stomach.
   • Pivotal Evidence: The BOLT trial demonstrated an ORR of ~56% in locally advanced BCC, showing comparable clinical efficacy to vismodegib.

The Challenge of Class-Specific Adverse Effects

Hedgehog inhibitors display a nearly universal, debilitating class-specific adverse effect profile occurring in >70% to 80% of patients:

• Muscle Spasms / Cramps (>70%): Severe, painful, nocturnal skeletal muscle spasms (mediated by non-canonical SMO calcium-channel signaling in myofibers).
• Dysgeusia or Ageusia (>60%): Loss of taste sensation, leading to severe anorexia, loss of appetite, and profound weight loss.
• Alopecia (>60%): Diffuse thinning and hair loss across the scalp and body (Hedgehog signaling is essential for hair follicle cycling and anagen maintenance).
• Weight Loss and Asthenia (>40%): Clinically significant weight loss (>10% of body mass), chronic fatigue, and nausea.
• Treatment Discontinuation: Cumulative low-grade toxicities force up to 30% to 50% of patients to discontinue therapy prematurely. European guidelines recommend planned treatment holidays or intermittent maintenance schedules to sustain disease control.

Mechanisms of Acquired Hedgehog Inhibitor Resistance

Approximately 20% of patients develop secondary acquired resistance after initial clinical response:

• Secondary Mutations in SMO: The primary mechanism involves missense point mutations within the drug-binding pocket of the Smoothened receptor—most notably the SMO D473H mutation (which prevents vismodegib binding) or mutations at residues W281, V321, and Q477.
• Bypass Signaling: Downstream genomic amplification of GLI2, loss of the negative regulator SuFu, or crosstalk activation via the PI3K/AKT/mTOR and atypical protein kinase C (aPKC) signaling cascades, driving GLI transcription independently of SMO.

Second-Line Systemic Therapy: Cemiplimab (Anti-PD-1 Immunotherapy)

For patients with locally advanced or metastatic BCC who have experienced disease progression on Hedgehog pathway inhibitor therapy, or who are intolerant to Hedgehog inhibitors, the European Medicines Agency (EMA) and FDA have approved the immune checkpoint inhibitor cemiplimab:

• Mechanism: A fully human IgG4 monoclonal antibody targeting the Programmed Cell Death-1 (PD-1) receptor, preventing engagement with PD-L1 and PD-L2 to restore cytotoxic T-lymphocyte antitumor immunity.
• Dosing: 350 mg intravenously every 3 weeks.
• Efficacy: Demonstrates an objective response rate of approximately 30% in advanced BCC, with prolonged, durable clinical responses.